Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

$APYX
Medical/Dental Instruments
Health Care
Get the next $APYX alert in real time by email

Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin

CLEARWATER, Fla., March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category. The NewBeauty Awards franchise is a leading and trusted program in the beauty space. The award winners represent effective solutions to consumers' biggest beauty interests, concerns, and trends.

Renuvion is the only device FDA-cleared for use after liposuction and is raising the bar for what consumers should expect from body contouring treatments. With more than 90 evidence-based clinical publications and long-lasting durable results from just one treatment, Renuvion has garnered a global fan base of consumers and plastic surgeons alike. This recognition comes at a pivotal time as consumers increasingly focus on the issue of loose and lax skin. According to Spate research, searches for "sagging skin" have surged by 168.7% in 2024 compared to the previous year.2

"We are proud to have Renuvion's game-changing technology receive this accolade by a trusted authority in the aesthetic space," said Charlie Goodwin, President, and CEO of Apyx Medical. "Thousands of plastic surgeons rely on Renuvion, the #1 body contouring technology trusted by doctors3, to provide an effective solution to the challenges of loose skin."

NewBeauty editors tested thousands of products leading up to the 15th annual Awards Issue with the goal of selecting the most innovative beauty products, treatments, and trends. NewBeauty editors also collaborate with board-certified doctors and medical experts to determine the most effective, results-driven in-office treatments and post-procedure essentials.

To learn more about how Renuvion can address skin concerns, and find a provider near you, visit www.Renuvion.com.

1. Renuvion is intended for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue. Renuvion is intended for the coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

2. https://www.personalcareinsights.com/news/spate-search-data-suggests-innovative-opportunities-to-target-saggy-skin-and-nose-bumps.html

3. In an independent survey by Wakefield Research of 200 unaffiliated board certified or eligible cosmetic and plastic surgeons in the US where 4 out of 5 surgeons agree.

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com 

Media Contact: 

Kaplow Communications 

Renuvion@kaplow.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/renuvion-wins-2025-newbeauty-award-for-best-minimally-invasive-skin-tightener-302409524.html

SOURCE Renuvion

Get the next $APYX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APYX

DatePrice TargetRatingAnalyst
10/17/2024Neutral
BTIG Research
7/14/2023$8.00Overweight
Stephens
5/20/2022$12.00Buy
Lake Street
8/13/2021$12.00 → $14.00Market Outperform
JMP Securities
More analyst ratings

$APYX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

    Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla., March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category. The NewBeauty Awards franchise is a leading and trusted program in the beauty space. The award winners represent effective solutions to consumers' biggest beauty in

    $APYX
    Medical/Dental Instruments
    Health Care
  • Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

    The number of single-use handpiece units shipped in Q4 2024 exceeded expectations, increasing 5% overall and 20% in the U.S. compared to the same period last yearSubmitted a 510(k) premarket notification to the U.S. FDA for the AYON™ Body Contouring System ahead of schedule and preparing for a planned launch in the back half of 2025, pending clearanceManagement to host a conference call today at 8:30 a.m. ET CLEARWATER, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial

    $APYX
    Medical/Dental Instruments
    Health Care
  • Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

    CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international call

    $APYX
    Medical/Dental Instruments
    Health Care

$APYX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$APYX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$APYX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$APYX
SEC Filings

See more

$APYX
Leadership Updates

Live Leadership Updates

See more
  • Apyx Medical Corporation Announces Board Leadership Transition

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

    $APYX
    $PDSB
    $SSKN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

    NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

    $APYX
    $LNTH
    $PRTK
    $SCPH
    Medical/Dental Instruments
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Pharmaceutical Preparations

$APYX
Financials

Live finance-specific insights

See more
  • Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

    CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international call

    $APYX
    Medical/Dental Instruments
    Health Care
  • Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

    CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. Management will host a conference call at 8:00 a.m. Eastern Time on November 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13

    $APYX
    Medical/Dental Instruments
    Health Care
  • Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024 Financial Summary: Total revenue of $12.1 million, a decrease of 10% year-over-year. Advanced Energy revenue of $9.8 million, a decrease of 17% year-over-year. OEM revenue of $2.4 million, an increase of 29% year-over-year. Net loss attributable to stockholders of $6.6 million, an increase of $5.6 million, or 5

    $APYX
    Medical/Dental Instruments
    Health Care

$APYX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more